A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

NCT02259114 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

NUT Midline Carcinoma
Triple Negative Breast Cancer
Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation
Castrate-resistant Prostate Cancer
CRPC
Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Birabresib

Sponsor

Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)